Alexander M. Eggermont ASDR Annual Scientific Meeting 2019

Abstracts this author is presenting:

• Prognostic/predictive value of AJCC-8 staging in the phase 3 EORTC-1325/KEYNOTE-054 trial: pembrolizumab vs placebo in resected high-risk stage III melanoma — Welcome and Session 1 - Melanoma